Telehealth Peptides Cost: 2026 Pricing Breakdown by Program

The question patients ask first about telehealth peptides is almost always cost. Not the molecular mechanism, not the FDA regulatory category, not the difference between Section 503A and 503B pharmacy compounding. Cost.

This article is the honest accounting. It walks through typical 2026 program-level pricing across the four most common telehealth peptide categories, explains exactly what is and is not included in the price, describes why insurance generally does not cover compounded peptide therapy, and lays out the math for comparing month-to-month enrollment against prepay and annual structures.

What the article does not do is compare compounded preparations to branded FDA-approved finished drug products by name or price. That comparison is not a meaningful one — compounded preparations and branded FDA-approved drugs occupy different regulatory categories under federal law, and per the FDA's February 6 2026 guidance, compounded products may not be marketed by comparison to branded products. The pricing here is for the compounded program category on its own terms.

Typical 2026 telehealth peptide program pricing

Telehealth peptide therapy is typically priced as a flat monthly program fee rather than a per-prescription unit cost. The flat fee aligns the patient's payment with what the program actually delivers: a continuing prescriber relationship, ongoing medication supply, and scheduled follow-up. Below are representative ranges across the four most common program categories TelePeptide offers.

Compounded GLP-1 receptor agonist programs

Programs centered on compounded semaglutide or tirzepatide are the most commonly searched telehealth peptide pricing category. Typical 2026 monthly ranges:

• Entry / microdose program: roughly $199 to $299 per month. Lower compounded doses, monthly fills, suitable for the initial titration window.
• Standard program: roughly $299 to $449 per month. Standard prescribed doses for ongoing metabolic care, with prescriber-led titration.
• Advanced program: roughly $449 to $599 per month. Higher prescribed doses where clinically appropriate.

These ranges reflect the compounded preparation specifically. Branded GLP-1 finished drug products are priced separately by their manufacturers and dispensed through retail or specialty pharmacies; TelePeptide does not dispense branded finished drug products. The two categories are not interchangeable and not directly comparable on price.

Sermorelin (GHRH analog) endocrine programs

Sermorelin is a growth-hormone-releasing hormone analog prescribed under endocrine evaluation for documented age-related GHRH-axis decline. The TelePeptide formulary includes sermorelin only within an endocrine-axis framing under prescriber supervision. Typical 2026 monthly ranges:

• Entry program: roughly $199 to $249 per month. Standard dosing under prescriber supervision.
• Standard program: roughly $249 to $349 per month. Includes endocrine follow-up labs at clinically appropriate intervals.

Sermorelin formulations are typically simpler to compound than GLP-1 receptor agonists, which is why the average monthly price runs lower for sermorelin programs at comparable dosing frequency.

NAD+ subcutaneous protocols

NAD+ telehealth protocols vary in dose and frequency. Typical 2026 monthly ranges:

• Entry program: $200 to $300 per month, typically 50 to 100 mg twice weekly.
• Standard program: $300 to $400 per month, typically 100 mg twice or three times weekly.
• High-dose program: $400 to $600 per month, with per-session dose at 150 to 200 mg.

The per-milligram math and the structural cost difference between subcutaneous protocols and clinic IV infusions is covered in detail in our NAD+ cost breakdown article.

B12 / MIC nutrient programs

Methylcobalamin (B12), lipotropic injections (MIC — methionine, inositol, choline), and related non-controlled compounded preparations are typically the lowest-cost category in the telehealth peptide / compounded nutrient family. Typical 2026 monthly ranges:

• Entry program: $99 to $149 per month for B12-only or MIC-only protocols.
• Standard program: $149 to $199 per month for combined or higher-dose protocols.

These preparations are typically non-sterile or simple sterile formulations, with lower API cost per dose, which is reflected in the program-level pricing.

What is included in the program fee

A telehealth peptide therapy program fee is bundled. Understanding the bundle matters because the pricing comparison across providers is not always apples-to-apples — some providers exclude items that others include, and the apparent low-cost provider may actually cost more once the unbundled items are accounted for.

The standard inclusion bundle at TelePeptide and most legitimate clinician-supervised telehealth peptide providers covers:

• Clinical evaluation. The initial review of the patient's intake form by a licensed clinician, including history review, medication reconciliation, contraindication screening, and treatment-goal discussion. Synchronous video where state law requires it; asynchronous review otherwise.
• Patient-specific prescription. The electronic prescription transmitted to the 503A compounding pharmacy.
• Compounded medication. The medication itself, prepared by a state-licensed Section 503A pharmacy operating under USP <797> (sterile) or USP <795> (non-sterile) standards.
• Supplies. Syringes, needles, alcohol swabs, sharps disposal guidance.
• Shipping. Temperature-controlled overnight delivery where the formulation requires cold-chain.
• Prescriber-portal messaging. Patients can reach their assigned prescriber through HIPAA-compliant secure messaging in the patient portal.
• Scheduled follow-up. Lab follow-up at week 6, week 12, and every 6 months thereafter as clinically indicated. Prescriber check-in at clinically appropriate intervals.
• Adverse event reporting access. The dedicated reporting pathway at /report-side-effects with 24-hour clinical acknowledgment.

What is NOT included

The items below are typically billed separately or fall outside the program scope entirely. Understanding the exclusions is what makes the comparison honest.

• Additional lab work beyond the initial panel. When the prescriber orders labs at a follow-up interval, those are billed at the lab's cash-pay rate (typically $50 to $300 per panel depending on the specific tests). Some patients use insurance for lab work even when paying cash for the medication; this is permitted and often more economical for the lab component.
• Dose escalations that change the prescribed formulation strength. A standard titration within the prescribed range typically does not trigger a new program fee, but a clinician-determined escalation to a different compounded strength can require a new prescription cycle that may carry an incremental cost.
• Ancillary care. Care for unrelated conditions is outside the scope of the telehealth peptide program. Patients may need a primary care provider for general healthcare needs.
• In-person physical exams. TelePeptide is a telemedicine platform. In-person exams, if a clinical situation requires one, would be obtained from a local provider at the patient's expense.
• Specialist referrals. Specialist care is referred to local providers and billed separately by those providers.
• Care outside the prescriber's scope. Acute care, urgent care, emergency care — these are not telehealth peptide therapy and are not within the program scope. Patients with emergencies call 911.

The compliance summary on the telehealth peptides hub lays out the full scope of what TelePeptide will and will not do clinically.

Why insurance does not cover compounded peptide therapy

This is the single most common cost question after the headline price. The answer is structural, not a quirk of any one insurance carrier.

Compounded peptide preparations are not FDA-approved finished drug products. They are prepared by Section 503A compounding pharmacies under federal pharmacy law, for a specific patient, in response to a patient-specific prescription. That regulatory category is distinct from the FDA-approved finished drug product category — the category that contains the medications insurance carriers typically cover.

Insurance carriers structure formularies around FDA-approved drugs prescribed for FDA-approved indications. Compounded preparations, even when clinically equivalent in mechanism, are not on the formulary because they are not in the FDA-approved finished drug product category. The exclusion is by regulatory category, not by therapeutic merit.

A few narrow exceptions exist:

• FSA and HSA accounts sometimes reimburse compounded peptide therapy when the prescriber documents a qualifying medical diagnosis. FSA/HSA administrators vary in what they accept.
• Specific qualifying diagnoses under certain plans may permit reimbursement for the compounded preparation. This is fact-specific to the plan and the prescriber's documentation.
• Self-funded employer plans occasionally cover compounded preparations under their formulary discretion. Patients can check with their plan administrator.

For the overwhelming majority of patients, however, telehealth peptide therapy is paid for out of pocket — that is what "cash-pay" means in this context.

What "cash-pay" actually means

"Cash-pay" is shorthand for a direct payment model: the patient pays the program fee to the telehealth provider, no insurance carrier is involved, and there is no expectation of post-hoc reimbursement.

The trade-offs are visible:

• Price transparency. The patient sees the program fee, understands what it includes, and knows what they will pay before they enroll. There is no claims cycle, no deductible math, no EOB to interpret weeks later.
• No prior authorization. The clinical decision rests with the prescriber and the patient. There is no insurance gatekeeping.
• No insurance-dictated formulary. Compounded preparations outside the insurance formulary are accessible because the formulary is not part of the equation.
• Full out-of-pocket cost. The patient bears the full cost. There is no benefit dollar offset.

For patients pursuing compounded peptide therapy, the cash-pay model is typically the only available structure because the underlying medication category is generally outside insurance coverage in any case. The cash-pay model is not a workaround — it is how the regulated category actually flows.

Comparison framework: per-month vs prepay vs annual

Most telehealth peptide programs offer multiple enrollment durations with different per-month effective pricing. The decision is about cash-flow timing and the patient's confidence in the program at the time of enrollment.

Month-to-month. Highest flexibility. No commitment beyond the current month. Highest per-month price. Best fit for patients who want to evaluate the program for the first 1 to 3 months before committing further.

3-month prepay. Modest per-month discount (commonly 5 to 10%) in exchange for prepaying three months at once. Best fit for patients who are confident in the protocol and want a small cost reduction with limited cash-flow impact.

6-month or annual prepay. Larger per-month discount (commonly 10 to 20%) in exchange for prepaying the longer term. Best fit for patients on protocols that are typically multi-month or multi-year by clinical design (e.g., ongoing metabolic care, ongoing endocrine support) and who can absorb the larger upfront payment.

The economic logic is symmetrical to other subscription healthcare models. The provider benefits from predictable revenue and reduced churn; the patient benefits from a lower per-month rate in exchange for committing to the longer term.

Comparing telehealth peptide providers on price

A few notes on doing the comparison honestly:

• Compare inclusion bundles, not headline prices. A $249/month program that excludes shipping, follow-up labs, and prescriber messaging may actually cost more than a $349/month program that includes all of them.
• Confirm the pharmacy is a Section 503A licensee. A program that ships from a non-pharmacy vendor at a low price is not in the prescription-pharmacy category at all — see our getting telehealth peptides legally guide for the warning signs.
• Confirm the prescribing clinician is licensed in your state. Out-of-state prescribing is permitted only under each state's telehealth practice act terms.
• Confirm public disclosure of the medical group. Reputable providers publicly name the medical group that renders care. TelePeptide discloses MD Integrations, P.C. — a contracted medical group operating a multi-state network of licensed physicians, NPs, and PAs.
• Ignore comparisons to branded FDA-approved finished drug products. Such comparisons are not regulatory-compliant and are not meaningful — the two categories are different products under federal law.

For the full menu of TelePeptide-offered programs, see the programs index. For the brand-disambiguation overview of TelePeptide itself, see the TelePeptide page.

The takeaway

Telehealth peptide therapy in 2026 is a cash-pay clinical service typically priced at a flat monthly program fee between $99 and $599 depending on the program, the active ingredient, and the dose. The fee bundles the clinical evaluation, prescription, compounded medication, dispensing, shipping, and prescriber follow-up. Additional labs, dose escalations to a different formulation strength, and ancillary care fall outside the bundle.

Insurance generally does not cover compounded peptide therapy because compounded preparations are not FDA-approved finished drug products and fall outside typical insurance formularies. Cash-pay is the standard payment model, and for most patients pursuing this category of care, it is the only available structure.

The honest comparison across providers is at the inclusion-bundle level, not at the headline-price level, and it depends on confirming each provider operates as a legitimate clinician-supervised telehealth peptide therapy program — a prescriber-patient relationship, a state-licensed 503A pharmacy, a public medical-group disclosure, and a clear adverse-event reporting pathway. Programs without those elements are not equivalent at any price.

Compounded by licensed 503A pharmacies. Not FDA-approved as finished drug products. Clinical services provided by MD Integrations, P.C. — a contracted medical group operating a multi-state network of licensed physicians, NPs, and PAs. Available in 48 US states + DC (excludes AK and MS). Not medical advice. Individual results vary.